<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21714">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932112</url>
  </required_header>
  <id_info>
    <org_study_id>APPLE</org_study_id>
    <nct_id>NCT01932112</nct_id>
  </id_info>
  <brief_title>Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)</brief_title>
  <acronym>APPLE</acronym>
  <official_title>Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators studied the effects of adenosine on the reconnection rate  after
      successful pulmonary veins isolation by radiofrequency catheter ablation  in patients with
      drug-resistant atrial fibrillation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary vein isolation has emerged as an effective therapy for paroxysmal atrial
      fibrillation. However, atrial fibrillation recurs in up to 50% of patients, generally
      because of recovery of pulmonary vein conduction.

      Adenosine given during the initial procedure may reveal dormant pulmonary vein conduction,
      thereby identifying the need for additional ablation, leading to improved outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reconnection of pulmonary vein electrogram after adenosine infusion</measure>
    <time_frame>5 minutes after IV adenosine</time_frame>
    <safety_issue>No</safety_issue>
    <description>After pulmonary vein isolation, 12mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation recurrence</measure>
    <time_frame>between 0 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At 1 month, 3 month, 6 month and 12 months post ablation routine clinic visits, will perform electrocardiographically documented by electrogram (At 1,3,6,12 months post ablation) and Holter monitoring (At 12 months post ablation)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Persistent Common Pulmonary Vein</condition>
  <arm_group>
    <arm_group_label>Adenosine arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After pulmonary vein isolation, 12mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine arm</intervention_name>
    <description>After pulmonary vein isolation, 12mg Iv adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.</description>
    <arm_group_label>Adenosine arm</arm_group_label>
    <other_name>APPLE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed atrial fibrillation

          -  recurrence of symptomatic atrial fibrillation in spite of Antiarrhythmic drug use

          -  written informed consent

        Exclusion Criteria:

          -  intracardiac thrombus

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong seog Oh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Seog OH, MD</last_name>
    <phone>82-2-2258-1141</phone>
    <email>oys@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul st Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-Ku</state>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Seog Oh, MD</last_name>
      <phone>82-2-2258-1141</phone>
      <email>oys@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong Seog Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Yong Seog Oh</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Vein Isolation</keyword>
  <keyword>Adenosin effect</keyword>
  <keyword>Atrial fibrillation ablation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
